Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation

Signalling from receptor tyrosine kinases is elicited by ligand binding which initiates the activation of many downstream signalling cascades. Endocytosis has been widely accepted as one mechanism in which cells inactivate signalling by internalising and subsequently degrading activated receptors. However, it is now evident that endocytosis of signalling receptors is important in initiation and sustaining downstream signalling. We and others have previously shown that epidermal growth factor receptor (EGFR) overexpression and activation of signal transducer and activator of transcription 3 (Stat3) are associated with tumourigenicity. Here, we examine the role of endocytosis in EGFR signal attenuation and differential signalling. Inhibition of dynamin II (Dyn II), a GTPase required for endocytosis, with a small molecular weight inhibitor, led to reduced EGF-mediated Stat3 phosphorylation and transcriptional activity in the A431 and HN5 human tumour cell lines. However, Dyn II inhibition had minimal effect on EGF-mediated EGFR and Erk1/2 phosphorylation, which is often regarded responsible for the tumourigenic function of the EGFR. Interestingly, this effect on Stat3 activation was not due to reduced EGFR/Stat3 association. Likewise, cells transfected with Dyn II siRNA or stably transfected with Dyn II shRNA had reduced EGF-mediated phospho-Stat3 levels but similar EGF-mediated phospho-EGFR and phospho-Erk1/2 levels compared with controls. Dyn II siRNA also reduced Stat3 transcriptional reporter activity and inhibits Stat3 accumulating into the nucleus. Taken together, our data suggest that the activation status of Stat3 and Erk1/2 and the sustainability of these signals are potentially due to the spatial and temporal control of the EGFR within the cell. This notion may have implications on therapeutic targeting and efficacy when using inhibitors to proteins either regulating endocytosis and/or signalling.

[1]  Hongying Shen,et al.  Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane , 2012, Proceedings of the National Academy of Sciences.

[2]  A. Sorkin,et al.  Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.

[3]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[4]  Kristopher C. Carver,et al.  SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. , 2009, Molecular endocrinology.

[5]  G. Cestra,et al.  CAP (Cbl associated protein) regulates receptor‐mediated endocytosis , 2009, FEBS letters.

[6]  P. Parker,et al.  Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation , 2008, The Journal of cell biology.

[7]  P. P. Di Fiore,et al.  Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. , 2008, Developmental cell.

[8]  P. Sehgal Paradigm shifts in the cell biology of STAT signaling. , 2008, Seminars in cell & developmental biology.

[9]  I. Madshus,et al.  Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis , 2008, Journal of cellular and molecular medicine.

[10]  J. Engelman,et al.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy. , 2008, Current opinion in genetics & development.

[11]  Antony W Burgess,et al.  EGFR family: Structure physiology signalling and therapeutic targets† , 2008, Growth factors.

[12]  Chen Chen,et al.  Myristyl Trimethyl Ammonium Bromide and Octadecyl Trimethyl Ammonium Bromide Are Surface-Active Small Molecule Dynamin Inhibitors that Block Endocytosis Mediated by Dynamin I or Dynamin II , 2007, Molecular Pharmacology.

[13]  P. Sehgal,et al.  Live cell imaging of interleukin-6-induced targeting of "transcription factor" STAT3 to sequestering endosomes in the cytoplasm. , 2007, American journal of physiology. Cell physiology.

[14]  B. van Deurs,et al.  EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. , 2007, Carcinogenesis.

[15]  Careen K. Tang,et al.  Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII , 2006, Cancer biology & therapy.

[16]  S. Stafford,et al.  Differential Regulation of Interleukin 5-stimulated Signaling Pathways by Dynamin* , 2006, Journal of Biological Chemistry.

[17]  M. McNiven,et al.  A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. , 2006, Cancer research.

[18]  R. Abagyan,et al.  Small molecule inhibitors of dynamin I GTPase activity: development of dimeric tyrphostins. , 2005, Journal of medicinal chemistry.

[19]  N. Pedersen,et al.  Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation , 2005, Journal of cellular biochemistry.

[20]  P. Transidico,et al.  Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Jeffrey L. Wrana,et al.  Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling , 2005, Nature Reviews Molecular Cell Biology.

[22]  J. Grandis,et al.  The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. , 2004, Seminars in oncology.

[23]  J. Turkson,et al.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. , 2004, Molecular cancer therapeutics.

[24]  Mamoru Tamura,et al.  Molecular dynamics of STAT3 on IL-6 signaling pathway in living cells. , 2004, Biochemical and biophysical research communications.

[25]  A. Scott,et al.  The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR , 2004, Oncogene.

[26]  W. Marshall,et al.  Analysis of Clathrin-mediated Endocytosis of Epidermal Growth Factor Receptor by RNA Interference*[boxs] , 2004, Journal of Biological Chemistry.

[27]  R. Weinberg,et al.  Heart and Liver Defects and Reduced Transforming Growth Factor β2 Sensitivity in Transforming Growth Factor β Type III Receptor-Deficient Embryos , 2003, Molecular and Cellular Biology.

[28]  A. Burgess,et al.  Epidermal Growth Factor Receptor: Association of Extracellular Domain Negatively Regulates Intracellular Kinase Activation in the Absence of Ligand , 2003, Growth factors.

[29]  Z. Ren,et al.  ErbB-2 Activates Stat3α in a Src- and JAK2-dependent Manner* , 2002, The Journal of Biological Chemistry.

[30]  Mark von Zastrow,et al.  Signal transduction and endocytosis: close encounters of many kinds , 2002, Nature Reviews Molecular Cell Biology.

[31]  J. Turkson,et al.  Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis , 2002, The EMBO journal.

[32]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  A. Scott,et al.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.

[34]  I. Mills,et al.  GTPase activity of dynamin and resulting conformation change are essential for endocytosis , 2001, Nature.

[35]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[36]  A. Miyajima,et al.  Receptor Subunit-specific Action of Oncostatin M in Hepatic Cells and Its Modulation by Leukemia Inhibitory Factor* , 2000, The Journal of Biological Chemistry.

[37]  I. Verlaan,et al.  Dynamin Is Required for the Activation of Mitogen-activated Protein (MAP) Kinase by MAP Kinase Kinase* , 1999, The Journal of Biological Chemistry.

[38]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[39]  Monilola A. Olayioye,et al.  ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.

[40]  A. Tobin,et al.  Activation of the Mitogen-activated Protein Kinase Pathway by a Gq/11-coupled Muscarinic Receptor Is Independent of Receptor Internalization* , 1999, The Journal of Biological Chemistry.

[41]  L. E. Johannessen,et al.  High-affinity Binding of Epidermal Growth Factor (EGF) to EGF Receptor Is Disrupted by Overexpression of Mutant Dynamin (K44A)* , 1998, The Journal of Biological Chemistry.

[42]  S. Schmid,et al.  Ubiquitously expressed dynamin-II has a higher intrinsic GTPase activity and a greater propensity for self-assembly than neuronal dynamin-I. , 1997, Molecular biology of the cell.

[43]  J. Schlessinger,et al.  Specific role for the PH domain of dynamin‐1 in the regulation of rapid endocytosis in adrenal chromaffin cells , 1997, The EMBO journal.

[44]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[45]  S. Schmid,et al.  Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis , 1996, Science.

[46]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[47]  S. Schmid,et al.  Induction of mutant dynamin specifically blocks endocytic coated vesicle formation , 1994, The Journal of cell biology.

[48]  J. Welsh,et al.  Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.

[49]  A. Sorkin,et al.  Endocytosis and intracellular trafficking of ErbBs. , 2008, Experimental cell research.

[50]  P. Stahl,et al.  Role of rab5 in EGF receptor-mediated signal transduction. , 2004, European journal of cell biology.

[51]  J. Wrana,et al.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. , 2003, Nature cell biology.

[52]  Z. Ren,et al.  ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. , 2002, The Journal of biological chemistry.

[53]  J. Hinshaw Dynamin and Its Role in Membrane Fission , 2022 .